Bergmark BA, Bhatt DL, McGuire DK, et al. - Researchers estimated the impact of metformin exposure on clinical outcomes in patients with type 2 diabetes mellitus (T2D) in this post hoc analysis of the SAVOR-TIMI 53 trial. Inverse probability of treatment weighting Cox modeling was used to estimate the links between metformin exposure and outcomes. Even after adjustment for clinical variables and biomarkers, lower rates of all-cause mortality were reported in relation to metformin use in a cohort of 12,156 patients with T2D and high cardiovascular (CV) risk. However, no reduction was evident in the rates of the composite endpoint of CV death, myocardial infarction, or ischemic stroke. In patients without prior HF or moderate to severe CKD, this link was most apparent.